Skip to main content
All lobbying filings

Jeffrey J. Kimbell & Associates, Inc.

Jeffrey J. Kimbell & Associates, Inc. filed a Q4 termination amendment for Biogen Inc. on April 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Biogen Inc. · Global biotechnology company

As filed: JEFFREY J. KIMBELL & ASSOCIATES, INC. for BIOGEN INC.

All filings by Jeffrey J. Kimbell & Associates, Inc. · Everything Biogen Inc. has reported

 Filing · LD-2 quarterly report Q4 termination amendment
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Apr 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Massachusetts
Representation ended
Dec 17, 2025
The registrant reported terminating its work for this client.

Official filing document

 Lobbyists on this filing 5
  • KEITH STUDDARD
    Previously held: Legislative Director, Rep. Marsha Blackburn
  • JOHN R RAY
    Previously held: Legislative Assistant, Rep. Mike Kelly
  • JOHN HERZOG
    Previously held: Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President
  • LAURA KEMPER
    Previously held: Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services
  • BRETT MEEKS
    Previously held: Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Medicare/Medicaid

Issues related to Medicare Part B and Part D

Health Issues

Issues related to the pharmaceutical industry

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem